List of Publications on aHUS

Causes Krishnappa V. 2017 Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens Meta-analysis yes
Treatment Van de Walle 2017 Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. Case studies yes
Overview Yoshida 2017 Atypical hemolytic uremic syndrome ( in Japan) Summary yes
Trigger Raufi 2016 Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab Case Studies yes
Diagnosis Barnard 1965 THE HAEMOLYTIC-URAEMIC SYNDROME OF INFANCY Case studies yes
Diagnosis Symmer 1952 Thrombotic Microangiopathic Haemolytic Anaemia Article yes
Treatment Cheong 2016 Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea Guidelines yes
Extra Renal Involvement Hofer J 2014 Extra-renal manifestations of complement-mediated thrombotic microangiopathies Article yes
Extra Renal Involvement Ardissino G 2013 Skin Involvement in Atypical Hemolytic Uremic Syndrome pdf yes
Overview Noris 2016 Genetic Atypical Hemolytic-Uremic Syndrome NCBI GeneReview yes
Registry Woodward 2016 An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry Article yes
Treatment Licht 2015 Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Study yes
Triggers Yasuda 2016 Postoperative Atypical Hemolytic Uremic Syndrome Treated Successfully with Eculizumab. Case study yes
Triggers Thadjudeen 2013 A case of atypical hemolytic uremic syndrome successfully treated with eculizumab. Case study yes
Treatment Fakouri 2013 Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Study no
Treatment Legendre 2013 Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. Trial yes
Treatment Sheerin 2016 A national specialized service in England for atypical haemolytic uraemic syndrome-the first year’s experience. Study no
Treatment Wong 2015 Patient stratification and therapy in atypical haemolytic uraemic // (aHUS). Study no
Treatment Wong 2015 Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Lit. no
Treatment Morgan 2015 Complement, a target for therapy in inflammatory and degenerative diseases. Lit. no
Treatment Kaplan 2014 Current treatment of atypical hemolytic uremic syndrome Study yes
Treatment Richardo 2014 Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases Study yes
Treatment Scully 2014 How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome Study yes
Treatment Westra 2012 A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Study no
Treatment Risitano 2011 Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases Study yes
Transplant Xie Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Case study no
Transplant Okumi 2016 Prevention and treatment of atypical hemolytic uremic syndrome after kidney transplantation. Study no
Transplant Zuber 2012 Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Trial yes
Secondary aHUS de Fontbrun 2015 Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. Case study no
Secondary aHUS Jodele 2016 Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to OptimizeTherapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Study no
Secondary aHUS Jodele 2016 The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Study no
Secondary aHUS Li 2015 Clinical characteristics of hemolytic uremic syndrome secondary to cobalamin C disorder in Chinese children. Case study no
Secondary aHUS Cornec le Gall 2014 Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Case study no
Secondary aHUS Shiari 2014 Atypical hemolytic-uremic syndrome associated with antiphospholipid antibodies and antiphospholipid syndrome; a novel presentation Case study no
Secondary aHUS Menni 2012 Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Case study no
Secondary aHUS Hale 2005 Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Study yes
Secondary aHUS Jodele 2014 Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Case study yes
Registry Licht 2015 The global aHUS registry: methodology and initial patient characteristics. Study yes
Pregnancy Fakouri 2016 Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Study no
Pregnancy Thomas 2016 How we manage thrombotic microangiopathies in pregnancy. Study no
Pregnancy Goodship 2010 Pulling the Trigger in Atypical Hemolytic Uremic Syndrome: The Role of Pregnancy Study yes
Pregancy Fakouri 2010 Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations Study yes
Genetic Causes Warwicker 1998 Genetic studies into inherited and sporadic hemolytic uremic syndrome. Study yes
Eculizumab Pereira Palma 2016 Critical appraisal of eculizumab for atypical hemolytic uremic syndrome Study yes
Eculizumab Greenbaum 2016 Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Trial yes
Eculizumab Fakouri 2014 Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Study yes
Diagnosis Akesson 2016 Indications of underdiagnosis of Atypical Hemolytic Uremic Syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012. Study no
Causes Miyata 2016 No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome Study no
Causes Rigothier 2015 Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody. Case study no
Causes Norris 2015 Podocyte dysfunction in atypical haemolytic uraemic syndrome. Study no
Causes Mele 2015 Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Case study no
Causes Bernabeu-Herroro 2015 Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Study no
Causes Diamante Chiodini 2014 Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Case study no
Causes Westland 2014 Phenotypic expansion of DGKE-associated diseases. Case study yes
Causes Sansbury 2014 Factors determining penetrance in familial atypical haemolytic uraemic syndrome Study no
Causes Bu 2014 Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. Study no
Causes Rodriguez de Cordoba 2014 Genetics of atypical hemolytic uremic syndrome (aHUS) Study no
Causes Meri 2013 Complement activation in diseases presenting with thrombotic microangiopathy. Study no
Causes Fremeaux- Baachi 2013 Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Study no
Causes Dragon-Durey 2010 Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome Study yes
Causes Gasser 1955 [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Case study no